Research Resources

National Brain Tumor Society’s Research Resources highlights page features our latest research papers, survey results, scientific data, industry information, and research results that help drive better treatments, and ultimately a cure, for brain tumors. Please click on the following topics to access the latest resources and articles.

For more information on our research results, scientific papers and programs, please contact Amanda Bates at 516.632.8880 or abates@braintumor.org.

About Us

Accordion Post

Conference Meeting Calendar

American Society for Clinical Oncology

American Society of Clinical Oncology
Was Held June 3-7, 2016
Chicago, IL

Learn more...

Society for Neuroscience

November 12-16, 2016 San Diego, CA

Learn more...

Society for Neuro-Oncology

November 17-20, 2016 Scottsdale, AZ

Learn more...

Defeat Pediatric Brain Tumors

Turn the Tide on Pediatric Brain Tumors

This content focuses on the latest information on NBTS’s program to fight pediatric brain tumors.

Learn more...

Glioblastoma / Defeat GBM

Defeat GBM Research Collaborative Retreat: An In-Person Meeting of the Minds

Since the commencement of research in 2014, the Defeat GBM Research Collaborative has developed an integrated scientific and drug discovery program focused on moving research from laboratory to clinical readiness. Now two years in, NBTS, together with Dr. Alfred Yung – Scientific Director of Defeat GBM – decided that it was a good time to […]

Learn more...

Defeat GBM Research Collaborative: Two-Year Progress Report

March 24, 2016
To date, the Defeat GBM Research Collaborative’s approach has been validated by successfully accelerating the process from research discovery to drug development by at least 1-2 years.

Learn more...

Defeat GBM Research Collaborative Updates and Research

The Defeat GBM Research Collaborative is a groundbreaking, research-based initiative that takes advantage of the convergence of exciting scientific advancements, an innovative business model, and support from biopharmaceutical companies to drive research forward with the aim of doubling the five-year survival rate of GBM patients.

Learn more...

Video – An Aggressive Leap Forward: Defeat GBM program

Video of key glioblastoma researchers highlighting National Brain Tumor Society’s Defeat GBM program and it’s impact and results.

Learn more...

Video – Scientific Summit 2015 – The Defeat GBM Research Collaborative introduction

Renowned researcher Dr. Al Yung opens up the Defeat GBM session at the 2015 NBTS Scientific Summit.

Learn more...

Improving Clinical Trials / Neuroimaging

Brain Tumor Groups come together for new Imaging Effort

A coalition of brain tumor organizations collaborate to build a set of standardized MRI protocols for brain tumor diagnosis.

Learn more...

Brain tumor clinical trials imaging: a (well-standardized) picture is worth a thousand words

(2015) Joohee Sul and Daniel M. Krainak. Neuro-Oncology 17(9), 1179–1180.

Learn more...

Standardized Brain Tumor Imaging Protocol for Clinical Trials

(2015) G.V. Goldmacher, B.M. Ellingson, J. Boxerman, D. Barboriak, W.B. Pope,and M. Gilbert. AJNR Am J Neuroradiol. 36(10):E65-6

Learn more...

Webinar to Discuss New Consensus Recommendations for a Standardized Brain Tumor Imaging Protocol (BTIP) in Neuro-Oncology Clinical Trials

Presenters:

  • Daniel Barboriak, MD, Duke University Medical Center, Professor of Radiology and Pediatrics, Department of Neuroradiology
  • Martin Bendszus, MD, University of Heidelberg (Germany), Chairman, Department of Neuroradiology
  • Benjamin Ellingson, PhD, MSc, University of California, Los Angeles, Associate Professor of Radiology, Biomedical Physics, Psychiatry, and Bioengineering; Director, UCLA Brain Tumor Imaging Laboratory; Co-Director, UCLA Center for Computer Vision and Imaging Biomarkers; Department of Radiological Sciences
  • Patrick Wen, MD, Brigham and Women’s/Dana-Farber Cancer Institute, Harvard Medical School, Director of the Center for Neuro-Oncology and Division of Cancer Neurology at BWH/Dana-Farber Cancer Institute
Learn more...

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

(2015) Benjamin M. Ellingson, Martin Bendszus, Jerrold Boxerman, Daniel Barboriak, Bradley J. Erickson, Marion Smits, Sarah J. Nelson, Elizabeth Gerstner, Brian Alexander, Gregory Goldmacher, Wolfgang Wick, Michael Vogelbaum, Michael Weller, Evanthia Galanis, Jayashree Kalpathy-Cramer, Lalitha Shankar, Paula Jacobs, Whitney B. Pope, Dewen Yang, Caroline Chung, Michael V. Knopp, Soonme Cha, Martin J. van den Bent, Susan Chang, W.K. Al Yung, Timothy F. Cloughesy, Patrick Y. Wen, Mark R. Gilbert, and the Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Neuro-Oncology 17(9), 1188–1198

Learn more...

Moving the Field Toward More Patient-Focused Drug Development

Together with our partners in the Jumpstarting Brain Tumor Drug Development Coalition – Accelerate Brain Cancer Cure (ABC2), Musella Foundation for Brain Tumor Research and Education, and the Society for Neuro-Oncology – NBTS has been advocating for the brain tumor research field to take patients’ quality of life into great account during clinical trials.

Learn more...

Industry / Field News

Optune Approval by FDA

Novocure’s Optune device has gained FDA approval as the latest treatment for brain tumors as used in conjunction with surgery and radiation therapy.

Learn more...

So You Heard About Rintega?

News broke that a promising clinical trial of a new type of treatment for a subset of glioblastoma (GBM) patients – an immunotherapeutic vaccine made by Celldex Therapeutics called RINTEGA (rindopepimut) – was discontinued.

Learn more...

Brain Tumor Research Highlights: July 2016

Included are highlights of some newly published research from the brain tumor scientific and medical community, compiled by NBTS Director of Research & Scientific Policy, Ann Kingston, PhD and NBTS Research Programs Associate, Amanda Bates

Learn more...

Brain Tumor Research Highlights: June 2016

Included are highlights of some newly published research from the brain tumor scientific and medical community, compiled by NBTS Director of Research & Scientific Policy, Ann Kingston, PhD and NBTS Research Programs Associate, Amanda Bates

Learn more...

ASCO 2016 Highlights

American Society of Clinical Oncology 2016 Annual Meeting, organized by American Society Of Clinical Oncology (ASCO) was be held on Jun 3 -7, 2016 at McCormick Place, Chicago, Illinois, USA.

Learn more...

10 Things You Need To Know About the New Cellphone Study

On Friday, May 27th, results from a highly anticipated, $25 million study conducted by the US National Toxicology Program hit the headlines and reignited the well-known debate about the connection between cellphone use and developing brain cancer.

Learn more...

Brain Tumor Research Updates: May 2016

Included are highlights of some newly published research from the brain tumor scientific and medical community, compiled by NBTS Director of Research & Scientific Policy, Ann Kingston, PhD and NBTS Research Programs Associate, Amanda Bates

Learn more...

60 Minutes, The Poliovirus, and Breakthrough Therapy Designation

Since the news program “60 Minutes” first aired two segments in March 2015 focused on an early-phase clinical trial taking place at Duke University, a lot of excitement has been generated about the investigational treatment highlighted: PVS-RIPO – more commonly referred to as the re-engineered poliovirus.

Learn more...

Research Updates: Recent NBTS-Funded Research

The ultimate goal of scientific endeavor in the field of cancer research is to advance discoveries made in the laboratory through the translational and pre-clinical research process to become new medicines patients can take in the clinic.

Learn more...

Moving the Field Toward More Patient-Focused Drug Development

Together with our partners in the Jumpstarting Brain Tumor Drug Development Coalition – Accelerate Brain Cancer Cure (ABC2), Musella Foundation for Brain Tumor Research and Education, and the Society for Neuro-Oncology – NBTS has been advocating for the brain tumor research field to take patients’ quality of life into great account during clinical trials.

Learn more...

World Health Organization (WHO) Updates Official Classification of Tumors of the Central Nervous System

On May 9, 2016, the World Health Organization (WHO) published an official reclassification of Tumor Types of the Central Nervous System, which has moved the greater neuro-oncology field toward a more precise and accurate system of brain tumor classification. Based on information from expert neuropathologists and neuro-oncologists, the result of the updated WHO classifications, which […]

Learn more...

The Neuro-Oncology Field Weighs-in: Predictions & Hopes for Brain Tumor Research Advances in 2016

In 2015 we saw a major swing toward positive momentum in the fight against brain tumors, and we’re carrying it into 2016. Last year we experienced the first new treatment for newly diagnosed glioblastoma patients approved to enter the market in nearly a decade, as well as the biggest single-year increase in funding for the […]

Learn more...

NBTS Funded Papers

Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance

Authors: Kenta Masui, Kazuhiro Tanaka, Shiro Ikegami, Genaro R. Villa, Huijun Yang, William H. Yong, Timothy F. Cloughesy, Kanato Yamagata, Nobutaka Arai, Webster K. Cavenee, and Paul S. Mischel

Journal: PNAS 2015; 112, 9406-9411

Learn more...

Targeted Sequencing in Chromosome 17q Linkage Region Identifies Familial Glioma Candidates in the Gliogene Consortium

Authors: Ali Jalali, E. Susan Amirian, Matthew N. Bainbridge, Georgina N. Armstrong,Yanhong Liu, Spyros Tsavachidis, Shalini N. Jhangiani, Sharon E. Plon, Ching C. Lau, Elizabeth B. Claus, Jill S. Barnholtz-Sloan,mDora Il’yasova, Joellen Schildkraut, Francis Ali-Osman, Siegal Sadetzki, Christoffer Johansen, Richard S. Houlston,Ro bert B. Jenkins, Daniel Lachance, Sara H. Olson, Jonine L. Bernstein, Ryan T. Merrell, Margaret R. Wrensch, Faith G. Davis, Rose Lai,Sanjay Shete, Kenneth Aldape,Christopher I. Amos, Donna M. Muzny, Richard A. Gibbs, Beatrice S. Melin, and Melissa L. Bondy

Journal: Scientific Reports 5, Article number: 8278 doi:10.1038/srep08278

Learn more...

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

Authors: Jeanette E. Eckel-Passow, Daniel H. Lachance, Annette M. Molinaro, Kyle M. Walsh, Paul A. Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L. Kosel, Ivan V. Smirnov, Gobinda Sarkar, Alissa A. Caron, Thomas M. Kollmeyer, Corinne E. Praska, Anisha R. Chada, Chandralekha Halder, Helen M. Hansen, Lucie S. McCoy, Paige M. Bracci, Roxanne Marshall, Shichun Zheng, Gerald F. Reis, Alexander R. Pico, Brian P. O’Neill, Jan C. Buckner, Caterina Giannini, Ph.D., Jason T. Huse, Arie Perry, Tarik Tihan, Mitchell S. Berger, Susan M. Chang, Michael D. Prados, Joseph Wiemels, John K. Wiencke, Margaret R. Wrensch, and Robert B. Jenkins,

Journal: N Engl J Med. 2015; 372, 2499-2508

Learn more...

Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time

Authors: Mi Zhou, Paige M. Bracci, Lucie S. McCoy, George Hsuang, Joseph L. Wiemels,Terri Rice, Shichun Zheng, Karl T. Kelsey, Margaret R. Wrensch, and John K. Wiencke

Journal: Int. J. Cancer 2015; 37:826-36

Learn more...

The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma

Authors: Sridevi Yadavilli, Joseph Scafidi, Oren J. Becher, Amanda M. Saratsis, Rebecca L. Hiner, Madhuri, Kambhampati, Santi Mariarita, Tobey J. MacDonald, Kari-Elise Codispoti, Suresh N. Magge, Jyoti K. Jaiswal, Roger J. Packer, and Javad Nazarian

Journal: Oncotarget, 2015; 6, 12141-12155.

Learn more...

Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma

Authors: Elias J. Sayour, Pat McLendon, Roger McLendon, Gabriel De Leon, Renee Reynolds, Jesse Kresak, John H. Sampson, and Duane A. Mitchell

Journal: Cancer Immunol Immunother. 2015; 64, 419-27

Learn more...

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

Authors: Owen Clark, Katharine Yen, and Ingo K. Mellinghoff

Journal:  Clin Cancer Res. 2016 ; Jan 27. pii: clincanres.1333.2015. (Advance open access online)

Learn more...

MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab

Authors: Robert J. Harris, Timothy F. Cloughesy, Anthony J. Hardy, Linda M. Liau, Whitney B. Pope, Phioanh L. Nghiemphu, Albert Lai and Benjamin M. Ellingson

Journal: Journal of Neuro-Oncology. 2015; 122, 497-505

Learn more...

Survival and low-grade glioma: the emergence of genetic information

Authors: Elizabeth B. Claus, Kyle M. Walsh, John K. Wiencke, Annette M. Molinaro, Joseph L. Wiemels, Joellen M. Schildkraut, Melissa L. Bondy, Mitchel Berger, Robert Jenkins, and Margaret R Wrensch

Journal: Neurosurg Focus. 2015; 38(1):E6

Learn more...

Epidermal growth factor receptor targeting and challenges in glioblastoma

Authors: Amy Haseley Thorne, Ciro Zanca, and Frank Furnari

Journal:  Neuro-Oncology 2016; doi:10.1093/neuonc/nov319 (Advance open access online)

Learn more...

Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma

Authors: Benjamin H. Beck, Hyunggoon Kim, Rebecca O’Brien, Martin R. Jadus, G. Yancey Gillespie, Gretchen A. Cloud, Neil T. Hoa4, Catherine P. Langford, Richard D. Lopez, Lualhati E. Harkins, and Lawrence S. Lamb Jr.

Journal: PLoS ONE 2015; 10(5): e0122387. doi:10.1371/journal.pone.0122387 d.

Learn more...

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma

Authors: Macarena I. de la Fuente, Robert J. Young, Jennifer Rubel, Marc Rosenblum, Jamie Tisnado, Samuel Briggs, Julio Arevalo-Perez, Justin R. Cross, Carl Campos, Kimberly Straley, Dongwei Zhu, Chuanhui Dong, Alissa Thomas, Antonio A. Omuro, Craig P. Nolan, Elena Pentsova, Thomas J. Kaley, Jung H. Oh, Ralph Noeske, Elizabeth Maher, Changho Choi, Philip H. Gutin, Andrei I. Holodny, Katharine Yen, Lisa M. DeAngelis, Ingo K. Mellinghoff, and Sunitha B. Thakur

Journal: Neuro-Oncology 2015; doi:10.1093/neuonc/nov307 (Advance open access online)

Learn more...

Mesenchymal Stem Cells Isolated from Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells through the IL- 6/gp130/STAT3 pathway

Authors: Anwar Hossain, Joy Gumin, Feng Gao, Javier Figueroa, Naoki Shinojima, Tatsuya Takezaki, Waldemar Priebe, Diana Villarreal, Seok-Gu Kang, Celine Joyce, Erik Sulman, Qianghu Wang, Frank C Marini, Michael Andreeff, Howard Colman, and Frederick Lang

Journal: Stem Cells. 2015; 33, 2400-15. doi: 10.1002/stem.2053.

Learn more...

The BRAF kinase domain promotes the development of gliomas in vivo

Authors: Clifford H. Shin, Allie H. Grossmann, Sheri L. Holmen, and James P. Robinson

Journal: Genes & Cancer 2016; 6, 1-2.

Learn more...

Quantification of nonenhancing tumor burden in gliomas using effective T2 maps derived from dual echo turbo spin echo MRI

Authors: Benjamin M. Ellingson, Albert Lai , HuyTram N Nguyen, Phioanh L Nghiemphu , Whitney B Pope, and Timothy F Cloughesy

Journal: Clin Cancer Res. 2015; 21, 4373-83

Learn more...

Insulator dysfunction and oncogene activation in IDH mutant gliomas

Authors: William A. Flavahan, Yotam Drier, Brian B. Liau, Shawn M. Gillespie, Andrew S. Venteicher, Anat o. Stemmer-Rachamimov, Mario L. Suvà and Bradley E. Bernstein

Journal: Nature 2015; Dec 23. doi: 10.1038/nature16490.

Learn more...

Genetic Modulation of Neurocognitive Function in Glioma Patients

Authors: Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Wefel

Journal: Clinical Cancer Research 2015; 21(14):3340-6

Learn more...

Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma

Authors: Warren Chang, Whitney B. Pope, Robert J. Harris, Anthony J. Hardy, Kevin Leu, Reema R. Mody, Phioanh L. Nghiemphu, Albert Lai, Timothy F. Cloughesy, and Benjamin M. Ellingson

Journal: Tomography 2015; 1, 37-43

Learn more...

Calibrating genomic and allelic coverage bias in single-cell sequencing

Authors: Cheng-Zhong Zhang, Viktor A. Adalsteinsson, Joshua Francis, Hauke Cornils, Joonil Jung, Cecile Maire, Keith L. Ligon, Matthew Meyerson, and J. Christopher Love

Journal: Nature Communications Apr 16;6:6822. doi: 10.1038/ncomms7822.

Learn more...

A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma.

Authors: Regina T Martuscello, Vinata Vedam-Mai, David J McCarthy, Michael E Schmoll, Musa A Jundi, Christopher D. Louviere, Benjamin Griffith, Colby L Skinner, Oleg Suslov1, Loic P Deleyrolle, and Brent A. Reynolds

Journal: Clin Cancer Res. 2015; December 2, 2015; doi: 10.1158/1078-0432.CCR-15-0916

Learn more...

CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas

Authors: Gerald F Reis, Melike Pekmezci, Helen M Hansen, Terri Rice, Roxanne E Marshall, Annette Molinaro, Joanna J Phillips, Hannes Vogel, John K Wiencke, Margaret R Wrensch, Kyle M Walsh, and Arie Perry

Journal: J. Neuropath Exp Neurol. 2015: 74, 442–452

Learn more...

mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment

Authors: Kenta Masui, Webster K. Cavenee, and Paul S. Mischel

Journal: Brain Pathology 2015; 25, 755–759

Learn more...

Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma

Authors: Frank B. Furnari, Timothy F. Cloughesy, Webster K. Cavenee, and Paul S. Mischel

Journal: Nat Rev Cancer. 2015 15, 302-10

Learn more...

Designing a broad-spectrum integrative approach for cancer prevention and treatment

Authors: Block et al.

Journal: Seminars in Cancer Biology 2015; 35, Suppl. S276–S304

Presentation also included: Open Presentation

Learn more...

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

Authors: Kazuhiro Tanaka,Takashi Sasayama,Yasuhiro Irino,Kumi Takata Hiroaki Nagashima, Naoko Satoh, Katsusuke Kyotani, Takashi Mizowaki, Taichiro Imahori,Yasuo Ejima, Kenta Masui, Beatrice Gini, Huijun Yang, Kohkichi Hosoda, Ryohei Sasaki, Paul S. Mischel, and Eiji Kohmura

Journal: J Clin Invest. 2015. 125:1591-602.

Learn more...

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling

Authors: Feng Liu, Gary C. Hon, Genaro R. Villa, Kristen M. Turner, Shiro Ikegami, Huijun Yang, Zhen Ye, Bin Li, Samantha Kuan, Ah Young Lee, Ciro Zanca, Bowen Wei, Greg Lucey, David Jenkins, Wei Zhang, Cathy L. Barr, Frank B. Furnari, Timothy F. Cloughesy, William H. Yong, Timothy C. Gahman, Andrew K. Shiau, Webster K. Cavenee, Bing Ren, and Paul S. Mischel

Journal: Molecular Cell 2015; 60, 1–13.

Learn more...

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

Authors: Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, Elizabeth A. Reap, Gary E. Archer, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, James E. Herndon II, April Coan, Roger E. McLendon, David A. Reardon, James J. Vredenburgh, Darell D. Bigner, and John H. Sampson

Journal: Nature 2015; 519(7543): 366–369.

Learn more...

STAT3 blockade inhibits a radiation-induced proneural-to-mesenchymal transition in glioma

Authors: Jasmine Lau, Shirin Ilkhanizadeh, Susan Wang, Yekaterina A. Miroshnikova, Nicolas A. Salvatierra, Robyn A. Wong, Christin Schmidt, Valerie M. Weaver, William A. Weiss, and Anders I. Persson

Journal: Cancer Res. 2015; 75, 4302-11

Learn more...

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

Authors: Milan G. Chheda, Patrick Y. Wen, Fred H. Hochberg, Andrew S. Chi, Jan Drappatz, April F. Eichler, Daniel Yang, Rameen Beroukhim, Andrew D. Norden, Elizabeth R. Gerstner, Rebecca A. Betensky, and Tracy T. Batchelor

Journal: J. Neuro-Oncology 2015: 121, 627-634

Learn more...

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Authors: Benjamin M. Ellingson, Martin Bendszus, Jerrold Boxerman, Daniel Barboriak, Bradley J. Erickson, Marion Smits, Sarah J. Nelson, Elizabeth Gerstner, Brian Alexander, Gregory Goldmacher, Wolfgang Wick, Michael Vogelbaum, Michael Weller, Evanthia Galanis, Jayashree Kalpathy-Cramer, Lalitha Shankar, Paula Jacobs, Whitney B. Pope, Dewen Yang, Caroline Chung, Michael V. Knopp, Soonme Cha, Martin J. van den Bent, Susan Chang, W.K. Al Yung, Timothy F. Cloughesy, Patrick Y. Wen, Mark R. Gilbert, and the Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee

Journal: Neuro-Oncology 2015; 17, 1188–1198

Learn more...

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma

Authors: Benjamin M. Ellingson, Eunhee Kim, Davis C. Woodworth, Helga Marques, Jerrold L. Boxerman, Yair Safriel, Robert C. McKinstry, Felix Bokstein, Rajan Jain, T. Linda Chi A., Gregory Sorensen, Mark R. Gilbert, and Daniel P. Barboriak

Journal: Int J. Oncol 2015 46(5):1883-92

Learn more...

PI3K pathway inhibition in GBM—is there a signal?

Authors: Donna Nichol and Ingo K. Mellinghoff

Journal: Neuro Oncology 2015; 17:1183-4

Learn more...

Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy

Authors: Jagadish C. Ghosh, Markus D. Siegelin, Valentina Vaira, Alice Faversani, Michele Tavecchio, Young Chan Chae, Sofia Lisanti, Paolo Rampini, Massimo Giroda, M. Cecilia Caino, Jae Ho Seo, Andrew V. Kossenkov, Ryan D. Michalek, David C. Schultz, Silvano Bosari, Lucia R. Languino, and Dario C. Altieri

Journal: JNCI 2015; 107 , dju502.

Learn more...

Oligodendroglioma / Low-grade Glioma

Video – Scientific Summit 2015 – Oligodendroglioma Research Fund

NBTS staff member Ann Kingston reviews research opportunities for the NBTS Oligodendroglioma Research Fund

Learn more...

Video – The Oligodendroglioma Research Fund

A discussion of how donated dollars are utilized as part of the Oligodendroglioma Research Fund.

Learn more...

National Brain Tumor Society Awards $1 Million in New Oligo Grants

NBTS announced new grant funding for four research projects studying a category of brain cancers known as low-grade gliomas, with particular focus on a rare brain tumor known as oligodendroglioma. Each grant awarded will provide $250,000 in funding over two years.

Learn more...

Recommended Papers

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Oct 23, 2008
Nature. 455(7216):1061-1068

Abstract
Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community. Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas–the most common type of adult brain cancer–and nucleotide sequence aberrations in 91 of the 206 glioblastomas. This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma. Furthermore, integration of mutation, DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications. Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer.

Learn more...

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

January, 2016
Cell. doi:10.1016/j.cell.2015.12.028

Highlights
•Comprehensive molecular profiling of 1,122 adult diffuse grade II, III, and IV gliomas
•Telomere length and telomere maintenance defined by somatic alterations
•DNA methylation profiling reveals subtypes of IDH mutant and IDH-wild-type glioma
•Integrated molecular analysis of progression from low-grade to high-grade disease

Learn more...

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

December 15, 2015
JAMA. 314(23): 2535-43

Importance Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Most patients die within 1 to 2 years of diagnosis. Tumor-treating fields (TTFields) are a locoregionally delivered antimitotic treatment that interferes with cell division and organelle assembly.

Learn more...

Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.

June 25, 2015
N Engl J Med. 372 (26):2481-2498

BACKGROUND
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas.

Learn more...

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

June 25, 2015
N Engl J Med. 372(26):2499-508

BACKGROUND

The prediction of clinical behavior, response to therapy, and outcome of infiltrative glioma is challenging. On the basis of previous studies of tumor biology, we defined five glioma molecular groups with the use of three alterations: mutations in the TERT promoter, mutations in IDH, and codeletion of chromosome arms 1p and 19q (1p/19q codeletion). We tested the hypothesis that within groups based on these features, tumors would have similar clinical variables, acquired somatic alterations, and germline variants.

Learn more...

The somatic genomic landscape of glioblastoma.

Oct 10, 2014

Abstract
We describe the landscape of somatic genomic alterations based on multi-dimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer.

Learn more...

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

May 18, 2010
Cancer Cell. 17(5):510-522

Abstract
We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples displays concerted hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype (G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors are younger at the time of diagnosis and experience significantly improved outcome. These findings identify G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds.

Learn more...

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Jan 19, 2011
Cancer Cell. 17(1):98-110

SUMMARY
The Cancer Genome Atlas Network recently catalogued recurrent genomic abnormalities in glioblastoma (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical and Mesenchymal subtypes and integrate multi-dimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define Classical, Mesenchymal, and Proneural, respectively. Gene signatures of normal brain cell types show a strong relation between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype with greatest benefit in Classical and no benefit in Proneural. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.

Learn more...

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

March 10, 2005
N Engl J Med. 352(10): 987-96

BACKGROUND
Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety.

Learn more...

Advance Research

Advocate for change